IDRI to continue development of inhalable TB drug candidate

(Infectious Disease Research Institute) IDRI (Infectious Disease Research Institute), on behalf of the Lilly TB Drug Discovery Initiative, announces it has entered into an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd., a China-based leading biopharmaceutical company, to continue development of inhalable CPZEN-45, a tuberculosis (TB) drug candidate that could potentially treat the growing problem of antibiotic-resistant TB.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news